In this issue, we dive into HAP studies, and the importance of an exert drug development solution partner in human abuse potential.

Click here to download a PDF, readable version of Issue 13: https://www.altasciences.com/sites/default/files/2022-04/The-Altascientist_issue3_HAP_2022_v3.pdf

CHAPTERS:

- 00:08 — Section 1: The FDA Takes Steps to Limit the Misuse and Abuse of Prescription Drugs

- 08:59 — Section 2: Altasciences' Human Abuse Potential (HAP) Study Services

- 11:32 — Section 3: Our Study Design and Protocol

- 15:24 — Section 4: Tips for Designing a HAP Study

- 17:40 — Section 5: Case Study

- 24:06 — Section 6: Pioneering Ongoing Research

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.